Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CAO Kelly Macdonald Sells 987 Shares
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CAO Kelly Macdonald sold 987 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $11.00, for a total transaction of $10,857.00. Following the sale, the chief accounting officer now owns 78,444 shares in the company, valued at $862,884. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of NASDAQ:IRWD traded up $0.02 during trading on Wednesday, reaching $11.37. 23,429 shares of the company were exchanged, compared to its average volume of 1,583,573. The firm has a market capitalization of $1.73 billion, a PE ratio of -12.02 and a beta of 1.80. The business’s fifty day simple moving average is $9.31 and its 200-day simple moving average is $10.08. Ironwood Pharmaceuticals, Inc. has a 12-month low of $7.91 and a 12-month high of $15.21.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, October 31st. The biotechnology company reported $0.40 EPS for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.30. The business had revenue of $131.17 million for the quarter, compared to analyst estimates of $97.10 million. Ironwood Pharmaceuticals had a negative net margin of 9.67% and a negative return on equity of 15.83%. The company’s quarterly revenue was up 99.7% compared to the same quarter last year. During the same period last year, the company posted ($0.27) earnings per share. On average, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.49 EPS for the current fiscal year.
A number of analysts recently weighed in on the stock. BidaskClub raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Wedbush increased their price objective on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. ValuEngine lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Cowen set a $12.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, September 13th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.50.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.